Henoch–Schönlein purpura

Signs and symptoms

Purpura, arthritis, and abdominal pain are known as the "classic triad" of Henoch–Schönlein purpura. Purpura occur in all cases, joint pains and arthritis in 80%, and abdominal pain in 62%. Some include gastrointestinal hemorrhage as a fourth criterion; this occurs in 33% of cases, sometimes, but not necessarily always, due to intussusception. The purpura typically appear on the legs and buttocks, but may also be seen on the arms, face and trunk. The abdominal pain is colicky in character, and may be accompanied by nausea, vomiting, constipation or diarrhea. There may be blood or mucus in the stools. The joints involved tend to be the ankles, knees, and elbows, but arthritis in the hands and feet is possible; the arthritis is nonerosive and hence causes no permanent deformity.

Of the 40% of patients who develop kidney involvement, almost all have evidence (visible or on urinalysis) of blood in the urine. More than half also have proteinuria (protein in the urine), which in one eighth is severe enough to cause nephrotic syndrome (generalised swelling due to low protein content of the blood). While abnormalities on urinalysis may continue for a long time, only 1% of all HSP patients develop chronic kidney disease.

Pathophysiology

Henoch–Schönlein purpura is a small-vessel vasculitis in which complexes of immunoglobulin A (IgA) and complement component 3 (C3) are deposited on arterioles, capillaries, and venules (hence it is a type III hypersensitivity reaction). The activation of the alternative complement pathway results in the deposition of IgA aggregates or IgA complexes in target organs (with deposition of C3). This leads to the production of inflammatory mediators, including vascular prostaglandins like prostacyclin, which may play a key role in the development of IgAV and its organ-specific clinical manifestations. As with IgA nephropathy, serum levels of IgA are high in HSP and there are identical findings on renal biopsy; however, IgA nephropathy has a predilection for young adults while HSP is more predominant among children. Further, IgA nephropathy typically only affects the kidneys while HSP is a systemic disease. HSP involves the skin and connective tissues, scrotum, joints, gastrointestinal tract and kidneys. The genetic basis remains unclear except for involvement of the human leukocyte antigen region of the genome. It is hypothesized to involve autoimmunity triggered by infections. Streptococcus strains and Parainfluenza virus are the most commonly associated pathogens, and in children Human Parvovirus B19 is a frequent viral trigger

Diagnosis

The diagnosis is based on the combination of the symptoms, as very few other diseases cause the same symptoms together. Blood tests may show elevated creatinine and urea levels (in kidney involvement), raised IgA levels (in about 50%), and raised C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) results; none are specific for Henoch–Schönlein purpura. The platelet count may be raised, and distinguishes it from diseases where low platelets are the cause of the purpura, such as idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.

If there is doubt about the cause of the skin lesions, a biopsy of the skin may be performed to distinguish the purpura from other diseases that cause it, such as vasculitis due to cryoglobulinemia; on microscopy, the appearances are of a hypersensitivity vasculitis, and immunofluorescence demonstrates IgA and C3 (a protein of the complement system) in the blood vessel wall. However, overall serum complement levels are normal.

On the basis of symptoms, it is possible to distinguish HSP from hypersensitivity vasculitis (HV). In a series comparing 85 HSP patients with 93 HV patients, five symptoms were found to be indicative of HSP: palpable purpura, abdominal angina, digestive tract hemorrhage (not due to intussussception), hematuria and age less than 20. The presence of three or more of these indicators has an 87% sensitivity for predicting HSP.

Biopsy of the kidney may be performed both to establish the diagnosis or to assess the severity of already suspected kidney disease. The main findings on kidney biopsy are increased cells and Ig deposition in the mesangium (part of the glomerulus, where blood is filtered), white blood cells, and the development of crescents. The changes are indistinguishable from those observed in IgA nephropathy.

HSP can develop after infections with streptococci (β-haemolytic, Lancefield group A), hepatitis B, herpes simplex virus, parvovirus B19, Coxsackievirus, adenovirus, Helicobacter pylori, measles, mumps, rubella, Mycoplasma and numerous others. Drugs linked to HSP, usually as an idiosyncratic reaction, include the antibiotics vancomycin and cefuroxime, ACE inhibitors enalapril and captopril, anti-inflammatory agent diclofenac, as well as ranitidine and streptokinase. Several diseases have been reported to be associated with HSP, often without a causative link. Only in about 35% of cases can HSP be traced to any of these causes.

The exact cause of HSP is unknown, but most of its features are due to the deposition of abnormal antibodies in the wall of blood vessels, leading to vasculitis. These antibodies are of the subclass IgA1 in polymers; it is uncertain whether the main cause is overproduction (in the digestive tract or the bone marrow) or decreased removal of abnormal IgA from the circulation. It is suspected that abnormalities in the IgA1 molecule may provide an explanation for its abnormal behaviour in both HSP and the related condition IgA nephropathy. One of the characteristics of IgA1 (and IgD) is the presence of an 18 amino acid-long "hinge region" between complement-fixating regions 1 and 2. Of the amino acids, half is proline, while the others are mainly serine and threonine. The majority of the serines and the threonines have elaborate sugar chains, connected through oxygen atoms (O-glycosylation). This process is thought to stabilise the IgA molecule and make it less prone to proteolysis. The first sugar is always N-acetyl-galactosamine (GalNAc), followed by other galactoses and sialic acid. In HSP and IgAN, these sugar chains appear to be deficient. The exact reason for these abnormalities is not known.

Classification

Multiple standards exist for defining Henoch–Schönlein purpura, including the 1990 American College of Rheumatology (ACR) classification and the 1994 Chapel Hill Consensus Conference (CHCC). Some have reported the ACR criteria to be more sensitive than those of the CHCC.

More recent classifications, the 2006 European League Against Rheumatism (EULAR) and Pediatric Rheumatology Society (PReS) classification, include palpable purpura as a mandatory criterion, together with at least one of the following findings: diffuse abdominal pain, predominant IgA deposition (confirmed on skin biopsy), acute arthritis in any joint, and renal involvement (as evidenced by the presence of blood and/or protein in the urine).

Differential diagnosis

Henoch–Schönlein purpura may present with an atypical manifestation, which can be confused with papular urticaria, systemic lupus erythematosus, meningococcemia, dermatitis herpetiformis, and acute hemorrhagic edema of infancy.

Treatment

As of 2017, the optimal way to treat Henoch–Schönlein purpura remains controversial. Analgesics may be needed for the abdominal and joint pains. Wound care is warranted if skin death and ulcerations occur. It is uncertain as to whether HSP needs treatment beyond controlling the symptoms. Most people do not receive therapy because of the high spontaneous recovery rate. Experts disagree on whether to routinely use corticosteroids as treatment for HSP. However, if they are given early in the disease episode, the duration of symptoms may be shortened, and abdominal pain can improve significantly. Moreover, the chance of severe kidney problems may be reduced. A systematic review did not find any evidence that steroid treatment (prednisone) is effective at decreasing the likelihood of developing long-term kidney disease.

Evidence of worsening kidney damage would normally prompt a kidney biopsy. Treatment may be indicated on the basis of the appearance of the biopsy sample; various treatments may be used, ranging from steroids by mouth to a combination of intravenous methylprednisolone (steroid), cyclophosphamide and dipyridamole followed by prednisone. Other regimens include steroids/azathioprine, and steroids/cyclophosphamide (with or without heparin and warfarin). Intravenous immunoglobulin (IVIG) is occasionally used.

There is no good evidence that treating children who have HSP with antiplatelet agent prevents persistent kidney disease. There is also no evidence that treating children or adults with cyclophosphamide prevents severe kidney disease. Heparin treatment is not justified for people with HSP.

Prognosis

Overall prognosis is good in most patients, with one study showing recovery occurring in 94% and 89% of children and adults, respectively (some having needed treatment). In children under ten, the condition recurs in about a third of all cases, usually within the four months of the initial attack. Recurrence is more common in older children and adults.

Kidney involvement

In adults, kidney involvement progresses to end-stage kidney disease (ESKD) more often than in children. In a UK series of 37 patients, 10 (27%) developed advanced kidney disease. Proteinuria, hypertension at presentation, and pathology features (crescentic changes, interstitial fibrosis and tubular atrophy) predicted progression.

The findings on renal biopsy correlate with the severity of symptoms: those with asymptomatic hematuria may only have focal mesangial proliferation while those with proteinuria may have marked cellular proliferation or even crescent formation. The number of crescentic glomeruli is an important prognostic factor in determining whether the patient will develop chronic renal disease.

In ESKD, some eventually need hemodialysis or equivalent renal replacement therapy (RRT). If a kidney transplant is found for a patient on RRT, the disease will recur in the graft (transplanted kidney) in about 35% of cases, and in 11%, the graft will fail completely (requiring resumption of the RRT and a further transplant).

Epidemiology

HSP occurs more often in children than in adults, and usually follows an upper respiratory tract infection. Half of affected patients are below the age of six, and 90% are under ten. It occurs about twice as often in boys as in girls.

Cases of HSP may occur anytime throughout the year, but some studies have found that fewer cases occur during the summer months.

History

The disease is named after Eduard Heinrich Henoch (1820–1910), a German pediatrician (nephew of Moritz Heinrich Romberg, the pioneer of neurology) and his teacher Johann Lukas Schönlein (1793–1864). Johann Schönlein described the condition as an entity in 1837; Eduard Heinrich Henoch in 1868 reported the first case of a patient with colic, bloody diarrhea, painful joints, and a rash. The English physician William Heberden (1710–1801) and the dermatologist Robert Willan (1757–1812) had already described the disease in 1802 and 1808, respectively, but the name Heberden–Willan disease has fallen into disuse. Moreover, Willan was the first to describe an exanthematous rash of childhood known as erythema infectiosum in 1799. In 1920, Eduard Glanzmann(1887-1959), a Swiss pediatrician noted for his contributions in the fields of infectious disease, vitamin therapy and, mostly the field of haematology. He recognised the role of allergy in the pathogenesis of Henoch–Schonlein purpura, hence the understanding of the allergic component in HSP. William Osler is also the first to recognise the underlying allergic mechanism of HSP. In 2012, the International Chapel Hill Consensus Conference Nomenclature of Vasculitides renamed HSP IgA vasculitis. Prior to this, the disease was more often known as Henoch–Schönlein purpura rather than the reverse.

In popular culture

The disease was featured in the TV series House in the season 6 episode "Open and Shut".

References

References

1. (January 2013). "2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides". Arthritis and Rheumatism.
2. (2007). "Dermatology". Mosby.
3. (March 1998). "Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients". Archives of Dermatology.
4. (August 2016). "Treatment Challenges, Uncertainty Abound with IgA Vasculitis". The Rheumatologist.
5. (August 1998). "Henoch-Schönlein purpura: a review". American Family Physician.
6. (November 1999). "Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature". Medicine.
7. Fauci AS. (1987). "Harrison's Book of Internal Medicine". McGraw Hill.
8. (January 2001). "Henoch-Schönlein purpura". Current Opinion in Rheumatology.
9. (April 2006). "Henoch Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population". QJM.
10. (2021). "Pathogenesis of IgA Vasculitis: An Up-To-Date Review". Frontiers in Immunology.
11. (February 1986). "Abnormalities of vascular prostaglandins in Henoch-Schönlein purpura". Archives of Disease in Childhood.
12. (March 2018). "Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review". Autoimmunity Reviews.
13. (November 2017). "Henoch-Schönlein Purpura: A Literature Review". Acta Dermato-Venereologica.
14. (May 1992). "Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders". The Journal of Rheumatology.
15. (December 1999). "Henoch-Schönlein purpura nephritis". Journal of the American Society of Nephrology.
16. (August 1990). "The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura". Arthritis and Rheumatism.
17. American College of Rheumatology. "1990 criteria for the classification of Henoch–Schönlein purpura".
18. (February 1994). "Nomenclature of systemic vasculitides. Proposal of an international consensus conference". Arthritis and Rheumatism.
19. (June 2002). "Problems of classification of Henoch Schonlein purpura: an Indian perspective". Clinical and Experimental Dermatology.
20. (July 2006). "EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides". Annals of the Rheumatic Diseases.
21. (August 2008). "Atypical clinical course of Henoch-Schonlein purpura". Canadian Family Physician.
22. (November 2017). "Henoch-Schönlein Purpura: A Literature Review". Acta Dermato-Venereologica.
23. (November 2007). "Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review". Pediatrics.
24. (February 2023). "Interventions for preventing and treating kidney disease in IgA vasculitis". The Cochrane Database of Systematic Reviews.
25. (2023-02-28). "Interventions for preventing and treating kidney disease in IgA vasculitis". The Cochrane Database of Systematic Reviews.
26. (August 2015). "Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)". The Cochrane Database of Systematic Reviews.
27. (May 1997). "Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome". Arthritis and Rheumatism.
28. (January 2012). "Henoch schonlein purpura--a 5-year review and proposed pathway". PLOS ONE.
29. (2002). "Epidemiology of Henoch-Schönlein purpura". Cleveland Clinic Journal of Medicine.
30. "Schönlein-Henoch purpura".
31. Hellman, Nathan. (2008-09-23). "Maladie de Berger".
32. (2002). "Dates in infectious diseases". Parthenon Pub. Group.
33. (1997). "GLANZMANN, Eduard". Springer.
34. {{WhoNamedIt. synd. 1022. Schönlein-Henoch purpura
35. (July 2022). "H20: Henoch–Schönlein purpura: what's in a name?". British Journal of Dermatology.
36. ""House" Open and Shut (TV Episode 2010) - Trivia".